Semaglutide Becomes Affordable After Patent Expiry

Semaglutide, one of the most important medical innovations in the treatment of type 2 diabetes and obesity, has entered a new era of accessibility following the expiry of Novo Nordisk’s patent in March 2026. For years, this drug was considered highly effective but prohibitively expensive, limiting its use to wealthier patients or those living in urban centers. The end of patent protection has changed that landscape dramatically, allowing generic manufacturers to introduce their own versions at far lower costs.

The transformation has been particularly significant in India, where the burden of diabetes and obesity is among the highest in the world. More than 100 million people live with type 2 diabetes, and over 250 million individuals are overweight or obese. Until recently, the high cost of semaglutide meant that only a small fraction of these patients could benefit from its therapeutic effects. Now, with generics flooding the market, the drug has become affordable for a much wider population, including those in tier‑2 and tier‑3 cities who previously had little access to advanced treatments.

The arrival of generics has also reshaped the pharmaceutical market. Within weeks of the patent expiry, dozens of companies launched their own formulations, creating intense competition and driving prices down further. This surge has not only democratized access domestically but is also expected to influence global affordability, as Indian generics often find their way into international markets. In response, the original manufacturer has adjusted its pricing strategies and sought partnerships to maintain relevance in a rapidly changing environment.

While the affordability of semaglutide is a major victory for public health, it also brings new challenges. Doctors warn that easier access could lead to misuse, particularly among individuals seeking the drug for cosmetic or lifestyle purposes rather than medical necessity. Regulatory oversight remains crucial, as semaglutide is still a prescription‑only medicine that requires careful monitoring to avoid complications such as gastrointestinal side effects or improper dosing. Patient education and medical supervision will therefore play a vital role in ensuring that the benefits of wider access are not undermined by unsafe practices.

Ultimately, the expiry of Novo Nordisk’s patent has ushered in a new chapter for semaglutide. What was once a costly treatment reserved for a select few is now within reach of millions. This shift represents not only a triumph of generic competition but also a turning point in the fight against two of the most pressing health challenges of our time—diabetes and obesity. The challenge ahead lies in balancing affordability with responsibility, ensuring that this powerful medicine is used safely and effectively to improve lives across the globe.